The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M., Chun, J. J. M., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 1,101–1,200 of 2,162
Ferreira, A., Saraiva, M., Behets, G. J. S., et al. (2009) · Journal of Nephrology · doi:10.1093/joneph/22.6.783 · Cited by 14
Drazen, J. M. (2006) · New England Journal of Medicine · doi:10.1056/nejme068175 · Cited by 13
Allanach, J. R., Fettig, N. M., Hardman, B. K., Rosen, A. R., Fan, V., Chung, C., Goldberg, E. J., Morse, Z. J., Shanina, I., Vorobeychik, G., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu5110 · Cited by 14
Humanized mouse as a tool to predict immunotoxicity of human biologics
Yong, K. S. M., Her, Z., Tan, S. Y., Tan, W. W. S., Liu, M., Lai, F., Heng, S. M., Fan, Y., Chang, K. T. E., Wang, C.-I., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.553362 · Cited by 13
“In addition, analysis of NHPs demonstrated differences in biological systems particularly that of the immune system, resulting in inconsistent correlation of possible immunotoxic side effects when tested with biologics designed with human-specific targets (5, 7, 64).”
BackgroundOh, J. H., Hild, B., Yoshida, T., Badger, J. H., Seishima, J., McCulloch, J. A., Jung, M. K., Azar, S., Trinchieri, G., & Rehermann, B. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.004 · Cited by 22
Oh, J. H., & Rehermann, B. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100426 · Cited by 13
Alveolar Type 2 Epithelial Cell Organoids: Focus on Culture Methods
Jain, K. G., Xi, N. M., Zhao, R., Ahmad, W., Ali, G., & Ji, H. (2023) · Biomedicines · doi:10.3390/biomedicines11113034 · Cited by 13
“Several studies have shown that drugs that were tested as safe in animal models failed clinical trials and caused life-threatening toxicity, multiorgan failure, and death in humans [95–97].”
BackgroundChallenges and opportunities of translating animal research into human trials in Ethiopia
Abrhaley, A., Giday, M., & Hailu, A. (2024) · BMC Medical Research Methodology · doi:10.1186/s12874-024-02338-8 · Cited by 14
“The adverse effects were due to differences in the drug’s target protein between species, leading to a more substantial human inflammatory response [43].”
BackgroundWei, Y., Li, R., Wang, Y., Fu, J., Liu, J., & Ma, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s466315 · Cited by 15
Ellerman, D. A. (2024) · BioDrugs · doi:10.1007/s40259-024-00691-0 · Cited by 13
“In a 2006 phase 1 trial, a CD28-agonist monoclonal antibody (TGN1412) led to life-threatening cytokine release syndrome in all six patients tested [101].”
Sun, Y., Zhou, L., Gu, X., Zhao, J., Bi, J., & Pan, L. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010140 · Cited by 19
“13 In another case, trials with an anti- 4-1BB agonistic mAb (urelumab) were terminated because of severe hepatotoxicity risks.”
Ramirez, C. M., Yeghiazarian, L., Hoh, R. A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021190 · Cited by 13
“Support for this latter perspective is based on several consistent observations, including: (1) measures of T cell activation rather than viral load predict outcome in the natural host of SIV [29], (2) measures of T cell activation in humans predict subsequent disease outcome independent of viral load [8,9,30], and (3…”
ResultZhang, Y., Doshi, S., & Zhu, M. (2015) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12663 · Cited by 13
Les « immune checkpoints », comment ça marche
Granier, C., Soumelis, V., Mandavit, M., Gibault, L., Belazzoug, R., Guillebon, É. D., Badoual, C., Tartour, É., & Roussel, H. (2017) · Annales de Pathologie · doi:10.1016/j.annpat.2016.12.007 · Cited by 16
An era of biological treatment in systemic lupus erythematosus
He, J., & Li, Z. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3933-x · Cited by 13
Bustos, R., Zapata, C., Esteban, E., Casallas, J. C. G., Jauregui, E. A., & Jaimes, D. A. (2018) · Sensors · doi:10.3390/s18030691 · Cited by 16
New Trials in Lupus and where Are we Going
Thanou, A., & Merrill, J. T. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0745-1 · Cited by 13
Cannarile, M. A., Gomes, B., Cañamero, M., Reis, B., Byrd, A. L., Charo, J., Yadav, M., & Karanikas, V. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2345 · Cited by 14
“Sudden and dramatic posttreatment increases in several cytokines demonstrates how an immune-mediated cytokine storm could culminate in multiorgan failure (121).”
BackgroundWang, X., Hahne, J., Li, L., et al. (2021) · Journal of Empirical Research on Human Research Ethics · doi:10.1177/1556264621995656 · Cited by 13
Gilbertson, S. E., & Weinmann, A. S. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.10.007 · Cited by 14
The importance of neopterin in COVID-19: The prognostic value and relation with the disease severity
Rasmi, Y., Heidari, N., Kırboğa, K. K., Hatamkhani, S., Tekin, B., Alipour, S., Naderi, R., Farnamian, Y., & Akça, İ. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.03.002 · Cited by 13
Pallocca, G. (2022) · ALTEX · doi:10.14573/altex.2207111 · Cited by 13
“More recently, human cell-based systems have been used increasingly, and it has become evident that some of the resources and focus directed to animal experiments may need to be shifted to clinical research and direct investigations of human pathology (Leist and Hartung, 2013; Seok et al., 2013; Suntharalingam et al.,…”
BackgroundColeman, R. A. (2011) · ISRN Pharmaceutics · doi:10.5402/2011/806789 · Cited by 17
Fundamentals of Clinical Immunotoxicology
House, R. V. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-401-2_24 · Cited by 13
Immunophenotyping: Application to Safety Assessment
Wang, X., & Lebrec, H. N. (2017) · Toxicologic Pathology · doi:10.1177/0192623317736742 · Cited by 15
“A well-known example is the severe adverse events observed with anti-CD28 superagonist monoclonal antibody Theralizumab (TGN-1412) in a human trial in the United Kingdom (Suntharalingam et al. 2006).”
Immunotherapy for cardiovascular disease
Martini, E., Stirparo, G. G., & Kallikourdis, M. (2017) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0717-306r · Cited by 13
Tragedies in Clinical Trials - A History Wrapped Up
Bansal, P., Gupta, S., Christopher, A. F., et al. (2015) · International Journal of Clinical Pharmacology & Toxicology · doi:10.19070/2167-910x-1500029 · Cited by 13
Bakács, T., Mehrishi, J. N., Szabados, T., Varga, L., Szabó, M., & Tusnády, G. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000103282 · Cited by 13
“This study included 451 healthy adults (18–64 years of age), who received 2 doses of the vaccine without adjuvant produced from a human isolate virus with the use of a plasmid rescue system. This vaccine was safe and had no remarkable adverse event profile. Nevertheless, its immunogenicity was poor to moderate at best…”
BackgroundAcute-Phase Reactants and the Concept of Inflammation
Kushner, I., & Ballou, S. P. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3285-4.10052-x · Cited by 13
Pathogenesis of multi-organic failure in autoimmune diseases
Amaral, M., & Alves, J. D. (2009) · Autoimmunity Reviews · doi:10.1016/j.autrev.2009.01.009 · Cited by 13
Modelling human immune responses using microbial exposures in rodents
Li, Y., & Baldridge, M. T. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01334-w · Cited by 12
Treg cells as a protective factor for Hashimoto`s thyroiditis: a Mendelian randomization study
Guo, J., Si, G., & Si, F. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1347695 · Cited by 18
“There is ongoing clinical development of a solitary CD28 agonist antibody, speci fi cally TAB 08 (TGN 1412) (57, 58).”
Six events that shaped antibody approvals in oncology
Paul, S., & Zhou, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1533796 · Cited by 12
Qin, Y., Li, M., & Liu, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1514335 · Cited by 12
“They conducted a Phase 1 trial using Tregs agonists in six healthy young volunteers (70).”
Upadhyay, S., Talagayev, V., Cho, S., Wolber, G., & Gabr, M. T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118194 · Cited by 13
Piccotti, J. R., Lebrec, H. N., Evans, E., Herzyk, D. J., Hastings, K. L., Burns‐Naas, L. A., Gourley, I. S., Wierda, D., & Kawabata, T. T. (2009) · Journal of Immunotoxicology · doi:10.1080/15476910802656440 · Cited by 12
CD28 Inhibits T Cell Adhesion by Recruiting CAPRI to the Plasma Membrane
Strazza, M., Azoulay‐Alfaguter, I., Dun, B., Baquero‐Buitrago, J., & Mor, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401492 · Cited by 11
Maschmeyer, I., & Kakava, S. (2020) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2020_135 · Cited by 16
Human-like Response of Pig T Cells to Superagonistic Anti-CD28 Monoclonal Antibodies
Uehlein, S., Ding, X., Flößer, J., Schmidt, S., Steitz, J., Bille, M., Schnitter, F., Baltes, S., Saalmüller, A., Gerner, W., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100174 · Cited by 15
Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction
Ahmad, R., & Haque, M. (2022) · Vaccines · doi:10.3390/vaccines10040614 · Cited by 17
“Systemic cytokine overproduction aggravates activation of macrophages as well as phagocytosis of erythrocytes, resulting in anemia [225,226].”
BackgroundThe expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment
Hassanian, H., Asadzadeh, Z., Baghbanzadeh, A., Derakhshani, A., Dufour, A., Khosroshahi, N. R., Najafi, S., Brunetti, O., Silvestris, N., & Baradaran, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938063 · Cited by 15
“Despite broader effects, the second approach is accompanied by more risk of dangerous adverse effects such as multiple organ failure due to cytokine storm caused by CD28 activating antibody, theralizumab (64).”
BackgroundmiR-aculous new avenues for cancer immunotherapy
Tang, W. W., Bauer, K. M., Barba, C., Ekiz, H. A., & O’Connell, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929677 · Cited by 15
“However, over-stimulation of T cells with aCD28 monoclonal antibody (mAb) led to severe lymphotoxicity and cytokine storm during a phase I clinical trial (59).”
BackgroundKaviani, E., Hosseini, A., Maymand, E. M., Ramzi, M., Ghaderi, A. A., & Ramezani, A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275777 · Cited by 12
Characterizing the immune response to myocardial infarction in pigs
Schnitter, F., Stangl, F., Noeske, E., Bille, M., Stadtmüller, A., Vogt, N., Sicklinger, F., Leuschner, F., Frey, A., Schreiber, W., et al. (2024) · Basic Research in Cardiology · doi:10.1007/s00395-024-01036-2 · Cited by 14
“In a first-in-human trial, intravenous bolus infusion of the respective anti-CD28 superagonist TGN1412 (TAB08) induced an unexpected severe cytokine release syndrome (CRS) [69].”
BackgroundQuality Assessment of Bioanalytical Quantification of Monoclonal Antibody Drugs
Lee, J. W., & Kelley, M. M. (2011) · Therapeutic Delivery · doi:10.4155/tde.10.99 · Cited by 12
A humanised mouse model of cytokine release: Comparison of CD3-specific antibody fragments
Malcolm, S., Smith, E., Bourne, T., & Shaw, S. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.07.001 · Cited by 12
Immunotherapy: opportunities, risks and future perspectives
Hildebrandt, M., Peggs, K. S., Uharek, L., Bollard, C. M., & Heslop, H. E. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.02.001 · Cited by 14
“As an example, the adverse effects surrounding a first-in-man clinical trial of a superagonistic T-cell–activating antibody (14) cast a spotlight on points to be considered when approaching cell-based immunotherapies, including”
BackgroundCD28 ligation increases macrophage suppression of T-cell proliferation
Silberman, D., Bucknum, A., Bartlett, T. M., Composto, G. M., Kozlowski, M., Walker, A., Werda, A., Cua, J., Sharpe, A. H., Somerville, J. E., et al. (2012) · Cellular and Molecular Immunology · doi:10.1038/cmi.2012.13 · Cited by 12
Intervention with costimulatory pathways as a therapeutic approach for graft-versus-host disease
Kwon, B. (2010) · Experimental & Molecular Medicine · doi:10.3858/emm.2010.42.10.071 · Cited by 12
“In 2006, when the fully humanized CD28 superagonist was first given to six healthy male volunteers, it triggered an immediate and severe cytokine release syndrome (Suntharalingam et al., 2006).”
BackgroundIn Vivo Antibiotic Removal During Coupled Plasma Filtration Adsorption
Page, M., Cohen, S., Ber, C.-É., et al. (2013) · ASAIO Journal · doi:10.1097/mat.0000000000000009 · Cited by 12
Modern Drug Discovery and Development
Salazar, D. E., & Gormley, G. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00041-7 · Cited by 20
Development of transplant immunosuppressive agents – considerations in the use of animal models
Costello, R., Kissenpfennig, A., Martins, P. N. A., & McDaid, J. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1535589 · Cited by 13
“The limitations of animal studies may have tragic consequences as was the case in the development of biological agent TGN 1412 [101,102,103].”
BackgroundThe Role of Costimulatory Pathways in Transplant Tolerance
Uehara, M., & McGrath, M. M. (2018) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2018.10.009 · Cited by 14
Tsan, M. (2019) · Journal of Empirical Research on Human Research Ethics · doi:10.1177/1556264619850710 · Cited by 12
Costimulation Immunotherapy in Allergies and Asthma
Mir, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802585-7.00004-2 · Cited by 12
Modulating LPS Signal Transduction at the LPS Receptor Complex with Synthetic Lipid A Analogues
White, A. F. B., & Demchenko, A. V. (2014) · Advances in carbohydrate chemistry and biochemistry · doi:10.1016/b978-0-12-800128-8.00005-4 · Cited by 13
Monoclonal antibodies generated by DNA immunization recognize CD2 from a broad range of primates
Brady, J. L., Mannering, S. I., Kireta, S., Coates, P. T. H., Proietto, A. I., Cowan, P. J., d’Apice, A. J. F., & Lew, A. M. (2009) · Immunology and Cell Biology · doi:10.1038/icb.2009.4 · Cited by 12
Vaccines and Vaccine Adjuvants as Biological Response Modifiers
Speil, C. A., & Rzepka, R. (2011) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2011.07.004 · Cited by 12
Miyasato, K., Takabatake, Y., Kaimori, J., Kimura, T., Kitamura, H., Kawachi, H., Li, X., Hünig, T., Takahara, S., Rakugi, H., et al. (2010) · Clinical and Experimental Nephrology · doi:10.1007/s10157-010-0370-4 · Cited by 12
“During our animal experiment, on 13 March 2006, humanized CD28SA, TGN1412, was administered to six healthy volunteers in London as part of a human phase I clinical trial, and serious, life-threatening adverse effects were reported [ 25 ].”
MethodRole of monoclonal antibodies in tumor-specific immunity
Nicodemus, C. F., Smith, L. M., & Schultes, B. C. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.331 · Cited by 12
Clinical Trials—Collecting Safety Data and Establishing the Adverse Drug Reactions Profile
Talbot, J. C. C., Keisu, M., & Ståhle, L. (2011) · Wiley eBooks · doi:10.1002/9780470975053.ch4 · Cited by 13
Eguren‐Santamaría, I., Melero, I., Rodríguez, I., Ortego, I., Armero, M., Gálvez‐Cancino, F., López‐Janeiro, Á., de Andrea, C. E., & Sanmamed, M. F. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011279 · Cited by 16
“101 102 Never-theless, preclinical NHP and clinical toxicity discordance examples 101 103 104 illustrate that interspecies differences extend beyond receptor sequence similarity and under-score the need for cautious FIH clinical trial designs.”
Agonizing over the Stimulatory Immune Checkpoint ICOS
Lee, J. C., & Fong, L. H. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1520 · Cited by 10
CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs
Zhang, J., Guo, Q., Wang, Q., & Duan, Y. (2022) · MedComm – Biomaterials and Applications · doi:10.1002/mba2.20 · Cited by 12
Application of DNA-based hydrogels as drug delivery system for immunomodulatory therapy
Cai, L., Mao, J., Wang, H., Chen, G., Xu, X.-L., Yuan, Q., & Chen, W. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104677 · Cited by 11
Immune checkpoints in rheumatoid arthritis: progress and promise
Small, A., Lowe, K., & Wechalekar, M. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285554 · Cited by 14
Better safe than sorry: dual targeting antibodies for cancer immunotherapy
Schoenfeld, K., Harwardt, J., & Kolmar, H. (2024) · Biological Chemistry · doi:10.1515/hsz-2023-0329 · Cited by 13
Majocchi, S., Lloveras, P., Nouveau, L., Legrand, M., Viandier, A., Malinge, P., Charreton, M., Raymond, C., Pace, E. A., Millard, B. L., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0298 · Cited by 12
“The first-in-human study of the high-affinity (1.88 nmol/L) SA anti-CD28 TGN1412 resulted in cata-strophic outcomes with cytokine release syndrome and multiorgan failure in all administered healthy volunteers (12).”
InfluentialCurrent status of phase I clinical trials in Asia: an academic perspectives.
Louisa, M., Takeuchi, M., Setiabudy, R., Nafrialdi, N., & Takeuchi, M. (2012) · PubMed · Cited by 11
Use of compassionate-case ATMP in preclinical data for clinical trial applications
Lowdell, M. W., Birchall, M., & Thrasher, A. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61018-6 · Cited by 11
Nuevas dianas terapéuticas en el lupus sistémico (parte 2/2)
Giraldo, W. A. S., Villanueva, M. J. G., Boteanu, A. L., et al. (2012) · Reumatología Clínica · doi:10.1016/j.reuma.2012.01.013 · Cited by 11
Funck‐Brentano, C., & Ménard, J. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.08.003 · Cited by 11
“The TGN 1412 accident occurred in London on 13 March 2006, and was published in the New England Journal of Medicine on 14 August 2006 [15], with an accompanying editorial and many letters.”
BackgroundEngineering a Dual Small Molecule Gated ZAP70 Switch in T Cells
Wong, N. M. L., & Wong, W. W. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.7b00394 · Cited by 12
Drug-induced thrombocytopenia: mechanisms and relevance in preclinical safety assessment
Narayanan, P. K., Henry, S. P., & Li, N. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.10.002 · Cited by 11
The progress to establish optimal animal models for the study of acute-on-chronic liver failure
Zhai, H., Zhang, J., Shang, D., Zhu, C., & Xiang, X. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1087274 · Cited by 15
Liang, S., Zheng, D., Liu, X., Mei, X., Zhou, C., Xiao, C., Qin, C., Yue, H., Lin, J., Liu, C., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1211759 · Cited by 13
“Such type of agonistic antibody may over-activate the immune system and cause severe cytokine storms (27, 28).”
BackgroundNonclinical Tools to Assess Risk of Drug Hypersensitivity Reactions
Whritenour, J., Casinghino, S. R., Collinge, M., & Zhu, X. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103354 · Cited by 10
Thaventhiran, T., Alhumeed, N., Yeang, H. X., Sethu, S., Downey, J. S., Alghanem, A. F., Olayanju, A., Smith, E., Cross, M. J., Webb, S. D., et al. (2014) · mAbs · doi:10.4161/mabs.29758 · Cited by 11
“TGN1412 is a CD28SA that caused an uncontrolled expansion of T cells with an accompanying cascade of proinflammatory cytokine release and infiltration of T cells into tissues, in all six healthy volunteers enrolled in a phase I clinical study.(3,4) Despite initial recovery, their conditions deteriorated and this may b…”
BackgroundInfluentialThompson, S., Dessi, J. L., & Self, C. H. (2009) · mAbs · doi:10.4161/mabs.1.4.9045 · Cited by 13
From “magic bullets” to specific cancer immunotherapy
Riether, C., Schürch, C. M., & Ochsenbein, A. F. (2013) · Swiss Medical Weekly · doi:10.4414/smw.2013.13734 · Cited by 11
Unveiling changes in the landscape of patient populations in cancer early drug development
Hierro, C., Azaro, A., Argilés, G., Élez, E., Gómez, P., Carles, J., & Rodon, J. A. (2016) · Oncotarget · doi:10.18632/oncotarget.13258 · Cited by 14
“Several ethical concerns arouse in 2006 with The TeGenero incident [46], where TGN1412 caused life-threatening toxicities and fostered the implementation of strict guidelines for EDD.”
BackgroundStabilizing Human Regulatory T Cells for Tolerance Inducing Immunotherapy
He, X., Koenen, H. J. P. M., Slaats, J., & Joosten, I. (2017) · Immunotherapy · doi:10.2217/imt-2017-0017 · Cited by 13
Sun, Y., Xie, J., Anyalebechi, J. C., Chen, C., Sun, H. Y., Xue, M., Liang, Z., Morrow, K. N., Coopersmith, C. M., & Ford, M. L. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000595 · Cited by 10
“Moreover, a clinical trial revealed that treatment with the anti-CD28 Ab TGN1412 led to rapid and severe cytokine storm in healthy humans (16).”
BackgroundRecruiting Healthy Volunteers for Research Participation via Internet Advertising
Bramstedt, K. A. (2007) · Clinical Medicine & Research · doi:10.3121/cmr.2007.718 · Cited by 11
Treatment and Prevention of Experimental Autoimmune Myocarditis with CD28 Superagonists
Wang, S., Liu, J., Wang, M., Zhang, J., & Wang, Z. (2009) · Cardiology · doi:10.1159/000256660 · Cited by 11
“Our study leads to the conclusion that the key cytokine IL-10 regulated the fate of T cells and induced the protection in myocarditis development in Lewis rats.In summary, these results have implications for the suppression of autoreactive effector T cells and autoantibodies induced to some extent by application of CD…”
ResultUpdate on Therapeutic Monoclonal Antibodies
Bussel, J. B., Giulino, L. B., Lee, S., Patel, V., Sandborg, C. I., & Stiehm, E. R. (2007) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2007.02.001 · Cited by 14
T cell trafficking and metabolism: novel mechanisms and targets for immunomodulation
Mauro, C., Fu, H., & Marelli‐Berg, F. M. (2012) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2012.02.018 · Cited by 13
“Special Exemptions”: Should They Be Put on Trial?
Gaspar, H. B., Swift, S. M., & Thrasher, A. J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.1 · Cited by 11
Adashek, M. L., & Feldman, M. (2019) · Journal of Oncology Practice · doi:10.1200/jop.19.00160 · Cited by 11
Costimulation Blockade in Transplantation
Yeung, M. Y., Grimmig, T., & Sayegh, M. H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_10 · Cited by 13
Informed Consent, Autonomy, and Beliefs
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0007 · Cited by 27
Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction
Abdel‐Rahman, S. A., Santini, B. L., Calvo‐Barreiro, L., Zacharias, M., & Gabr, M. T. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129599 · Cited by 12
Calvo‐Barreiro, L., Nada, H., Upadhyay, S., & Gabr, M. T. (2025) · ACS Omega · doi:10.1021/acsomega.5c10222 · Cited by 10
Assignment of quantities to biological medicines: an old problem re-discovered
Bristow, A. F. (2011) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2011.0175 · Cited by 10
Marini, B. L., Sun, Y., Burke, P. W., & Perissinotti, A. J. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216676633 · Cited by 10
Bhatty, M., Tan, W. F., Basco, M. D. S., Pruett, S. B., & Nanduri, B. (2016) · Alcohol · doi:10.1016/j.alcohol.2016.11.007 · Cited by 11
“Such a “cytokine storm” can also clearly cause adverse effects in humans (Suntharalingam et al., 2006), but the precise relationship between the effects of elevated pro-inflammatory mediators in humans and in mice is not entirely clear and remains the subject of active investigation and debate…”
Development of Cancer Immunotherapies
DeLucia, D. C., & Lee, J. K. (2022) · Cancer treatment and research · doi:10.1007/978-3-030-96376-7_1 · Cited by 15
Role of Cytokines as Immunomodulators
Kaur, H., & Ghorai, S. M. (2022) · Springer eBooks · doi:10.1007/978-981-16-6379-6_13 · Cited by 27
The landscape of biosimilars in Saudi Arabia: preparing for the next decade
Almutairi, A. R., Alsamil, A. M., Alsayyari, A., et al. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2235277 · Cited by 10
“The latter limitation is illustrated by the cytokine storm during the first human trial of anti-CD28 mAb (TGN1412), which could not be predicted from in vivo animal studies [16].”
BackgroundRecent Advances in Biotherapeutics Drug Discovery and Development
Zhong, X., Neumann, P. J., Corbo, M., & Loh, E. (2011) · InTech eBooks · doi:10.5772/28094 · Cited by 11
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.